Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 13Lung Neoplasms 6Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Neoplasms 2Carcinoma, Renal Cell 2Carcinoma 2Adenocarcinoma of Lung 2Thyroid Neoplasms 1Thoracic Neoplasms 1Squamous Non-Small Cell Lung Cancer 1Sarcoma, Synovial 1Sarcoma 1Rhabdoid Tumor 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Non Small Cell Lung Cancer ALK Positive or ROS1 Positive 1Neoplasms by Site 1Mesothelioma, Malignant 1Melanoma 1Lymphoma, Large-Cell, Anaplastic 1Lung Diseases 1Granuloma, Plasma Cell 1Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer 1EGFR T790M Mutation Positive NSCLC 1Desmoplastic Small Round Cell Tumor 1Colorectal Neoplasms 1Chondrosarcoma 1

Interventions

lorlatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
No longer available × Non Small Cell Lung Cancer ALK Positive or ROS1 Positive × Thoracic × Clear all
NCT03178071 2019-11-04

Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 Positive

Pfizer

No longer available
Thoracic

Non Small Cell Lung Cancer ALK Positive or ROS1 Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡